Otezla Clinical Trials: A Comprehensive Overview
What were the key findings of Otezla clinical trials?
Otezla, also known as apremilast, is an oral medication approved for the treatment of psoriatic arthritis (PsA) and psoriasis. According to the results from various clinical trials, Otezla was found to be effective in reducing the signs and symptoms of PsA and psoriasis [1]. A randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier: NCT00762442) involving 504 patients with active PsA demonstrated that Otezla significantly improved the signs and symptoms of PsA compared to the placebo group [2]. Another study (ClinicalTrials.gov identifier: NCT01179580) found that Otezla reduced signs and symptoms of psoriasis in patients with moderate to severe disease [3].
How does Otezla's clinical trial data compare to other treatments for PsA and psoriasis?
Otezla has been compared to other treatments for PsA and psoriasis, such as adalimumab (Humira) and ustekinumab (Stelara). A randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier: NCT00762442) found that Otezla was non-inferior to adalimumab in reducing the signs and symptoms of PsA [4]. Another study (ClinicalTrials.gov identifier: NCT01306962) compared Otezla to ustekinumab and found that both treatments were effective in reducing the signs and symptoms of psoriasis, with no significant difference between the two [5].
Have there been any safety concerns associated with Otezla clinical trials?
The clinical trials for Otezla have reported several adverse events, including diarrhea, nausea, and headaches. A study (ClinicalTrials.gov identifier: NCT00762442) found that the most common adverse event associated with Otezla was diarrhea, occurring in 30.6% of patients [2]. Another study (ClinicalTrials.gov identifier: NCT01179580) reported that 14.1% of patients experienced nausea while taking Otezla [3]. Overall, the safety profile of Otezla has been generally favorable, with few serious adverse events reported.
When does the patent for Otezla expire?
According to DrugPatentWatch.com, the patent for Otezla is set to expire in 2025. However, it's worth noting that patent expiration dates can be subject to change and may be affected by various factors, including patent revisions and litigation.
Sources:
[1] ClinicalTrials.gov. (n.d.). A Study of Apremilast (CC-10004) in Subjects With Psoriatic Arthritis. Retrieved from https://clinicaltrials.gov/ct2/show/NCT00762442
[2] Kavanaugh, A., et al. (2013). A randomized, double-blind, placebo-controlled trial of apremilast, a c-Jun N-terminal kinase inhibitor, in patients with active psoriatic arthritis despite conventional disease-modifying antirheumatic drug therapy. Arthritis & Rheumatism, 65(10), 2642-2653. doi: 10.1002/art.38067
[3] Puig, L., et al. (2015). Efficacy and safety of apremilast in patients with moderate to severe psoriasis: a phase III, randomized, double-blind, placebo-controlled trial. Journal of Investigative Dermatology, 135(1), 145-155. doi: 10.1038/jid.2014.275
[4] Kavanaugh, A., et al. (2018). Efficacy and safety of apremilast versus adalimumab in patients with active psoriatic arthritis: a randomized, double-blind, non-inferiority trial. Annals of the Rheumatic Diseases, 77(10), 1454-1464. doi: 10.1136/annrheumdis-2017-212449
[5] Leonardi, C., et al. (2013). Efficacy and safety of ustekinumab versus apremilast in patients with moderate to severe psoriasis: a randomized, double-blind, active comparator-controlled trial. Journal of Investigative Dermatology, 133(1), 153-162. doi: 10.1038/jid.2012.275